Baseline plasma proteomic analysis to identify biomarkers that predict radiation-induced lung toxicity in patients receiving radiation for non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 6, 2011, Pages 1073-1078

  Cai, Xu Wei ^a,b,c   Shedden, Kerby A ^d   Yuan, Shang Hu ^c   Davis, Mary A ^c   Xu, Lu Ying ^c,e   Xie, Cong Ying ^c,f   Fu, Xiao Long ^a,b   Lawrence, Theodore S ^c   Lubman, David M ^g   Kong, Feng Ming ^c,h  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e FUJIAN MEDICAL UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^h Veterans Administration Health Center   (United States)

Author keywords

Biomarker; Non small cell lung cancer; Proteomics; Radiation induced lung toxicity

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT COMPONENT C4B BINDING PROTEIN ALPHA SUBUNIT; PROTEOME; UNCLASSIFIED DRUG; VITRONECTIN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; FOLLOW UP; HUMAN; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RADIATION INJURY; RECEIVER OPERATING CHARACTERISTIC; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; THROMBOCYTE POOR PLASMA; WESTERN BLOTTING;

EID: 79958092570     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182152ba6     Document Type: Article

References (39)

1. Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973-985. (Pubitemid 32184604)
2. Kong FM, Ten Haken RK, Schipper MJ, et al. High-dose radiation improved local tumor control and overall survival in patients with inoperable/ unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. Int J Radiat Oncol Biol Phys 2005; 63:324-333. (Pubitemid 41317147)
3. Rosenzweig KE, Fox JL, Yorke E, et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma. Cancer 2005;103: 2118-2127. (Pubitemid 40605120)
4. Bradley J, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2005;61:318-328. (Pubitemid 40164423)
5. Anscher MS, Kong FM, Marks LB, et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997;37: 253-258. (Pubitemid 27138706)
6. Fu XL, Huang H, Bentel G, et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001;50:899-908. (Pubitemid 32594832)
7. Kong FM, Ten Haken R, Eisbruch A, et al. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 2005;32:S42-S54.
8. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008;41:615-625.
9. Latterich M, Abramovitz M, Leyland-Jones B. Proteomics: new technologies and clinical applications. Eur J Cancer 2008;44:2737-2741.
10. Koomen JM, Haura EB, Bepler G, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008;7:1780-1794.
11. Conrad DH, Goyette J, Thomas PS. Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Inter Med 2008;23:78-84. (Pubitemid 350295398)
12. Patz EF Jr, Campa MJ, Gottlin EB, et al. Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 2007;25:5578-5583.
13. Malard V, Prat O, Darrouzet E, et al. Proteomic analysis of the response of human lung cells to uranium. Proteomics 2005;5:4568-4580. (Pubitemid 41739934)
14. Ménard C, Johann D, Lowenthal M, et al. Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis. Cancer Res 2006;66:1844-1850. (Pubitemid 43259971)
15. Xu NY, Zhang SP, Nie JH, et al. Radon-induced proteomic profile of lung tissue in rats. J Toxicol Environ Health A 2008;71:361-366.
16. Ao X, Lubman DM, Davis MA, et al. Comparative proteomic analysis of radiation-induced changes in mouse lung: fibrosis-sensitive and -resistant strains. Radiat Res 2008;169:417-425. (Pubitemid 351620040)
17. Cai XW, Shedden K, Ao X, et al. Plasma proteomic analysis may identify new markers for radiation-induced lung toxicity in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010;77:867-876.
18. Chapet O, Kong FM, Quint LE, et al. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan. Int J Radiat Oncol Biol Phys 2005;63:170-178. (Pubitemid 41594455)
19. Kong FM, Hayman JA, Griffith KA, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 2006;65:1075-1086. (Pubitemid 44202245)
20. Sano K, Asanuma-Date K, Arisaka F, et al. Changes in glycosylation of vitronectin modulate multimerization and collagen binding during liver regeneration. Glycobiology 2007;17:784-794. (Pubitemid 47050665)
21. Chung LP, Bentley DR, Reid KB. Molecular cloning and characterization of the cDNA coding for C4b-binding protein, a regulatory protein of the classical pathway of the human complement system. Biochem J 1985;230:133-141. (Pubitemid 16247279)
22. Blom AM, Villoutreix BO, Dahlbäck B. Functions of human complement inhibitor C4b-binding protein in relation to its structure. Arch Immunol Ther Exp (Warsz) 2004;52:83-95. (Pubitemid 38685048)
23. Okroj M, Jenkins HT, Herbert AP, et al. Structural basis and functional effects of the interaction between complement inhibitor C4b-binding protein and DNA. Mol Immunol 2008;46:62-69.
24. Jenne D, Stanley KK. Nucleotide sequence and organization of the human S-protein gene: repeating peptide motifs in the "pexin" family and a model for their evolution. Biochemistry 1987;26:6735-6742. (Pubitemid 17153333)
25. Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol 1993;5:864-868.
26. Kamikubo Y, Okumura Y, Loskutoff DJ. Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin. J Biol Chem 2002;277:27109-27119. (Pubitemid 34951725)
27. Zhou A, Huntington JA, Pannu NS, et al. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 2003;10: 541-544. (Pubitemid 36792905)
28. Bunkenborg J, Pilch BJ, Podtelejnikov AV, et al. Screening for N-glycosylated proteins by liquid chromatography mass spectrometry. Proteomics 2004;4:454-465. (Pubitemid 38235265)
29. Liu T, Qian WJ, Gritsenko MA, et al. Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry. JProteome Res 2005;4:2070-2080. (Pubitemid 41814273)
30. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032-1037. (Pubitemid 41486985)
31. Uriarte SM, Powell DW, Luerman GC, et al. Comparison of proteins expressed on secretory vesicle membranes and plasma membranes of human neutrophils. J Immunol 2008;180:5575-5581.
32. Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. Int J Radiat Oncol Biol Phys 2009;74:1385-1390.
33. Schoppet M, Chavakis T, Al-Fakhri N, et al. Molecular interactions and functional interference between vitronectin and transforming growth factor-beta. Lab Invest 2002;82:37-46. (Pubitemid 34072644)
34. Parker T, Upton Z, Leavesley D. Vitronectin modulates human mesenchymal stem cell response to insulin-like growth factor-I and transforming growth factor beta 1 in a serum-free environment. Tissue Eng Part A 2009;15:1415-1426.
35. Junn E, Lee KN, Ju HR, et al. Requirement of hydrogen peroxide generation in TGF-beta 1 signal transduction in human lung fibroblast cells: involvement of hydrogen peroxide and Ca2+ in TGF-beta 1-in-duced IL-6 expression. J Immunol 2000;165:2190-2197. (Pubitemid 30643169)
36. Kyng KJ, May A, Brosh RM Jr, et al. The transcriptional response after oxidative stress is defective in Cockayne syndrome group B cells. Oncogene 2003;22:1135-1149. (Pubitemid 36367204)
37. Zhao L, Sheldon K, Chen M, et al. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. Lung Cancer 2008;59:232-239. (Pubitemid 351173403)
38. Suter L, Barnikol HU, Watanabe S, et al. [Rule of antibody structure. The primary structure of a monoclonal immunoglobulin L-chain of kappa-type, subgroup 3 (Bence-Jones protein Ti). IV. The complete amino acid sequence and its significance for the mechanism of antibody production]. Hoppe Seylers Z Physiol Chem 1972;353:189-208.
39. Kipps TJ, Tomhave E, Chen PP, et al. Autoantibody-associated kappa light chain variable region gene expressed in chronic lymphocytic leukemia with little or no somatic mutation. Implications for etiology and immunotherapy. J Exp Med 1988;167:840-852.